Unlike with blockade of IFNγ, which would impact the anti-tumour immunity47, IL23 blockade is unlikely to impede systemic, anti-cancer immunity, and neutralisation of the IL23 might even promote favourable cancer outcomes48–50. The gene discussed is IFNG; the disease is neoplasm.